The pharmaceutical industry is approaching one of the most consequential inflection points in its modern history. By 2027, patent expirations on a wave of blockbuster drugs will expose approximately $150 billion in annual revenue to generic and biosimilar competition — a reckoning that is already reshaping how companies build, defend, and monetize their intellectual property.
A Cliff, Not a Slope
Unlike previous cycles of patent expiration, this wave is notable for its concentration: a cluster of high-revenue medicines — including leading immunology, oncology, and cardiovascular therapies — face loss of exclusivity within a narrow window. For companies that have relied on a few flagship products to anchor their revenue base, the exposure is not gradual. It is abrupt.